<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01321775</url>
  </required_header>
  <id_info>
    <org_study_id>AVANTHER</org_study_id>
    <nct_id>NCT01321775</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer</brief_title>
  <official_title>Bevacizumab and Trastuzumab With Paclitaxel on Women With Her2+ Breast Cancer Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Madrid Sanchinarro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Madrid Sanchinarro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of the combined therapy Bevacizumab,
      trastuzumab and paclitaxel in neo-adjuvant therapy in patients with breast cancer HER 2+
      followed by surgery and adjuvant therapy (Cyclophosphamide, Trastuzumab and Doxorubicin
      liposomal).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic response in breast and axilla</measure>
    <time_frame>16 weeks average</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate tumor markers as potential predictors of the pathologic response</measure>
    <time_frame>baseline and 16 weeks average</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet</intervention_name>
    <description>Neo-adjuvant doses (12 weeks):
Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.
Adjuvant doses:
Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)</description>
    <arm_group_label>Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years

          -  Pre or post menopause patient with histology confirmation of breast cancer status II
             or III, Her2+ confirmed by FISH technique.

          -  Lesion bigger than 2cm.

          -  life expectancy &gt; 12 weeks.

          -  Normal Heart function (LVEF&gt;55%)

          -  Patient should give his/her signed, written informed consent.

        Exclusion Criteria:

          -  Previous chemotherapy treatment.

          -  Previous treatment with HER2 or VEGF inhibitors.

          -  Pulmonary disease not controlled.

          -  Hypertension not controlled (systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg) or
             significant cardiovascular disease (CVA/cerebral hemorrhage (6 months before
             inclusion), myocardial infarction (6 months before inclusion), unstable angina,
             congestive cardiac disease ≥ NYHA 2, or serious cardiac arrhythmia requiring
             medication.

          -  Antecedents of coagulopathy or clinically significant thrombosis.

          -  Major surgery, open biopsy or significant trauma 28 days before the inclusion in the
             study or planned major surgery during the study.

          -  Peripheral Neuropathy &gt; CTC 2 at inclusion.

          -  Altered renal function a. Creatinine &gt; 2.0 mg/dL or 177 mmol/L. b.Proteinuria &gt; 2+
             with reactive stick(dipstick). If screening proteinuria 2+, collection of 24h urine
             must show a value of proteins of 1 g/24h.

          -  Daily chronic treatment with corticosteroids

          -  Daily chronic treatment with aspirin (&gt; 325 mg/day) o clopidogrel (&gt; 75 mg/day)

          -  Antecedents or heritage evidence of bleeder diathesis or coagulopathy with risk of
             hemorrhage.

          -  Antecedents of abdominal fistula, gastrointestinal perforation or intra-abdominal
             abscess within 6 months previous to the inclusion.

          -  Active infection to be treated with iv antibiotics

          -  Serious injury not curing, peptic ulcer or bone fracture.

          -  Pregnant or active sexual patient not using contraceptive methods. or lactating woman

          -  Current or recent treatment with another IMP or participation in another clinical
             trial (30 days before inclusion)

          -  Another primary tumor (including primary brain tumors)within 5 years to the study
             inclusion, apart from in situ cervix carcinoma, skin squamous carcinoma, both if they
             are appropriately treated, or skin basal cell cancer if controlled.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Complejo Hospital Costa Del</name>
      <address>
        <city>Marbella</city>
        <state>Malaga</state>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Perez, MD</last_name>
      <phone>0034951 97 66 69</phone>
      <email>dipema2026@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Diego Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noelia Martinez, MD</last_name>
      <phone>003491 336 80 00</phone>
      <email>mjnoelia@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Noelia Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Garcia, MD</last_name>
      <phone>003491 756 78 50</phone>
      <email>lauraestevez@hospitaldemadrid.com</email>
    </contact>
    <investigator>
      <last_name>Laura Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2011</study_first_posted>
  <last_update_submitted>March 23, 2011</last_update_submitted>
  <last_update_submitted_qc>March 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sofia Perea</name_title>
    <organization>Fundación Hospital de Madrid</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

